Three Key Takeaways from the 43rd Annual J.P. Morgan Healthcare Conference
Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ground floor.
Novartis targeted radiation therapy gets FDA nod for advanced prostate cancer
The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four years ago.
Mayo Clinic Platform Program to Help Clinical Digital Health Startups Succeed
Mayo Clinic has developed a new tool that could speed up the time it takes for digital health companies to validate their tech to hospitals.
A leap forward in radiation therapy for brain tumors
Intracranial brachytherapy was recently improved through the development of a surgically targeted radiation therapy comprised of Cesium-131 radiation seeds embedded in a bioresorbable collagen tile.
Novartis radiopharmaceutical improves survival in key prostate cancer study
Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will present data from this pivotal study during the annual meeting of the American Society of Clinical Oncology.
Nanobiotix leverages physics to fight cancer
A French company is developing a technology that has the potential to magnify radiation doses without increasing damage to surrounding tissue.
Urologists v. Rad Oncs: New test shifts how doctors plan prostate cancer treatment
There are myriad prostate cancer screeners on the market, but a San Diego company’s test has an interesting spin: Researchers have found that the results of GenomeDx’s Decipher diagnostic shifts the way physicians recommend treatment for the disease, as seen in a recent Red Journal paper. The company’s genomic test, which it’s commercializing now, predicts the probability […]
Tackling Messy Provider Data with an NPI-Forward Approach
Mike Wirth of ProviderTrust shares insights about the company in this interview at the ViVE 2025 conference in Nashville last month.